Thomas Catinazzo Sells 187,163 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 187,163 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the sale, the chief financial officer owned 177,461 shares in the company, valued at approximately $3,011,513.17. This represents a 51.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $12.86, for a total transaction of $227,840.62.
• On Tuesday, April 28th, Thomas Catinazzo sold 972 shares of Relay Therapeutics stock. The stock was sold at an average price of $14.79, for a total transaction of $14,375.88.
• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $13.01, for a total transaction of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $27,000.00.

Relay Therapeutics Stock Up 3.4%

Shares of NASDAQ:RLAY traded up $0.59 during midday trading on Wednesday, reaching $18.03. The company’s stock had a trading volume of 4,593,884 shares, compared to its average volume of 3,258,751. The firm has a market capitalization of $3.45 billion, a PE ratio of -11.49 and a beta of 1.75. Relay Therapeutics, Inc. has a twelve month low of $3.03 and a twelve month high of $18.83. The stock has a fifty day moving average of $14.34 and a 200 day moving average of $10.97.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.58 million. Sell-side analysts anticipate that Relay Therapeutics, Inc. will post -1.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright boosted their price objective on Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. UBS Group set a $26.00 target price on Relay Therapeutics in a report on Tuesday, May 19th. Wall Street Zen raised Relay Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Guggenheim upped their price objective on Relay Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Finally, Barclays upped their price objective on Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Relay Therapeutics has an average rating of “Buy” and an average price target of $23.30.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Commodore Capital LP lifted its holdings in Relay Therapeutics by 27.3% in the 3rd quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock valued at $88,740,000 after purchasing an additional 3,650,000 shares in the last quarter. Casdin Capital LLC grew its holdings in shares of Relay Therapeutics by 14.7% during the fourth quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock worth $110,010,000 after buying an additional 1,662,193 shares in the last quarter. Perceptive Advisors LLC grew its holdings in shares of Relay Therapeutics by 412.3% during the first quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after buying an additional 7,847,896 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Relay Therapeutics by 3.1% in the fourth quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock valued at $81,990,000 after buying an additional 295,701 shares during the last quarter. Finally, Bellevue Group AG lifted its stake in shares of Relay Therapeutics by 1.4% in the third quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock worth $43,564,000 after buying an additional 114,740 shares in the last quarter. 96.98% of the stock is owned by institutional investors and hedge funds.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.